SCHEMBL4940240

SCHEMBL4940240

CCn1c(SCN2C=C(c3ccnc(C)c3)ON2)nnc1C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 2/20 0.33
PTK2 Q05397 1/20 0.33
ALDH1A1 P00352 4/20 0.33
KMT2A Q03164 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
TSHR P16473 2/20 0.33
MEN1 O00255 1/20 0.33
HDAC1 Q13547 1/20 0.32
ATM Q13315 1/20 0.32
TP53 P04637 1/20 0.31
S1PR1 P21453 1/20 0.31
CYP2D6 P10635 1/20 0.31
LMNA P02545 1/20 0.30
HPGD P15428 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4941967 0.81 MEN1 (0.47) ALDH1A1KMT2ATSHRMEN1TP53
SCHEMBL4947514 0.81 TSHR (0.38) ALDH1A1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL4939468 0.81 TSHR (0.47) ALDH1A1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL4940231 0.76 S1PR1 (0.31) S1PR1
SCHEMBL1545240 0.74 CYP3A4 (0.45) ALDH1A1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL5485303 0.74 DRD2 (0.41) ALDH1A1KMT2AMEN1TP53LMNA
SCHEMBL5489367 0.72 TSHR (0.49) ALDH1A1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL4946042 0.71 MAPT (0.45) ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4938300 0.68 MAPT (0.46) ALDH1A1KMT2ATSHRMEN1TP53
SCHEMBL4945592 0.66 TSHR (0.45) ALDH1A1KMT2ACYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045571-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045571-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS GRM5, GRIK5, GRM2 HDAC2 963/4885PTK2 2613/4885ALDH1A1 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.